hPAM4-Cide (yttrium Y-90 clivatuzumab tetraxetan) / Gilead  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
hPAM4-Cide (yttrium Y-90 clivatuzumab tetraxetan) / Gilead
NCT00597129: Safety and Efficacy Study of 90Y-hPAM4 at Different Doses

Completed
1/2
21
US
90Y-hPAM4, 111-IN-hPAM4, MUC-1 antibody
Gilead Sciences
Pancreatic Cancer
10/07
10/07
NCT00603863 / 2008-003993-16: Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer

Completed
1/2
80
US
IMMU-107 (hPAM4), hPAM4, IMMU-107, 90Y-hPAM4, anti-mucin antibody
Gilead Sciences
Pancreatic Cancer
07/13
12/13

Download Options